lifesciences
Innopsys

Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression To Invasive Breast Cancer

Alain Mangé1,2,3, Jérôme Lacombe1,2,3, Caroline Bascoul-Mollevi4, Marta Jarlier4, Pierre-Jean Lamy5, Philippe Rouanet6, Thierry Maudelonde1,2,3, and Jérôme Solassol1,2,3  1. CHU Montpellier, Hôpital Arnaud de Villeneuve, Department of Cellular Biology 2. University of Montpellier I; Departments of : 3. Clinical Oncoproteomics, 4. Biostatistics 5. Biology 6. And Suregy, Val d’Aurelle, Montpellier, France

Abstract

Purpose: The identification of markers associated with progression to invasive breast cancer (IBC) is a major factor that can guide physicians in the initial therapeutic decision and the management of ductal carcinoma in situ (DCIS).

HEAD OFFICE

Parc d'activités Activestre
31390 Carbonne - FRANCE

CONTACT

Phone +33 561 971 974
Fax +33 561 971 975